Amgen Inc has moved to strengthen its cardiovascular portfolio with the agreed purchase of Dezima Pharma BV of the Netherlands which has a new drug for dyslipidemia in a Phase 2b clinical trial. Dezima is backed by Forbion Capital Partners and other venture funds.
